Tarvacin
Tarvacin(TM) also useful in imaging solid tumors
By Peregrine Pharmaceuticals, Inc
Jul 31, 2005 - 11:13:00 PM

Peregrine Pharmaceuticals, Inc reported that data was presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California showing the potential use of Tarvacin(TM), its lead Anti-Phospholipid Therapy agent, for imaging solid tumors. The presentation talk was titled "Tumor Imaging With The Vascular Targeting Antibody Tarvacin(TM) Labeled with Arsenic Isotopes".

Data presented showed that Tarvacin(TM) could be used to deliver a radioactive arsenic compound to prostate cancer blood vessels for tumor imaging. An earlier presentation at the AACR Annual Meeting had shown the potential of Tarvacin(TM) for the treatment of prostate cancer. Peregrine expects to begin patient enrollment in a Tarvacin(TM) phase I clinical trial for the treatment of cancer within the next 30 days.

"These imaging data indicate another potential utility for Tarvacin(TM) and other agents that fall under our Anti-Phospholipid Therapy technology platform," said Steven King, president and CEO of Peregrine Pharmaceuticals. "We will continue to explore additional ways to fully utilize this technology platform for the treatment and therapy of cancer and other diseases. In addition to its anti-cancer activity, the company recently announced data showing Tarvacin's impressive anti-viral activity and the company has been evaluating the compound for activity in treating ocular disease."

All rights reserved by www.rxpgnews.com